Rituximab Treatment of Adult Patients with Steroid-resistant Focal Segmental Glomerulosclerosis

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2009 Jul 7

PMID 19578004

Citations 59

Authors

Gema Fernandez-Fresnedo

Alfonso Segarra

Ester Gonzalez

Simona Alexandru

Ramon Delgado

Natalia Ramos

Jesus Egido

Manuel Praga

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Isolated case reports have shown a beneficial effect of rituximab on pediatric patients with primary FSGS, but there is no information about rituximab treatment of FSGS in adults.

Design, Setting, Participants, & Measurements: All patients who had biopsy-proven FSGS and were treated with rituximab in Spain were identified, independent of their positive or negative response, among the nephrology departments that belong to the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Their characteristics and outcome after rituximab treatment were studied.

Results: Eight patients were identified. Rituximab failed to improve nephrotic syndrome in five of eight patients, who continued to show massive proteinuria and exhibited a rapidly deteriorating renal function in two cases. Among the remaining three patients, two of them showed an improvement of renal function and a remarkable proteinuria reduction and one experienced a beneficial but transitory effect after rituximab. There were no differences in clinical or laboratory characteristics or in the CD20 B lymphocyte count after rituximab between these three patients and the five who had a negative response. The only difference was in the regimen of rituximab administration: Whereas the five patients with a negative response received only four weekly consecutive infusions of 375 mg/m(2), the three remaining patients received additional doses of rituximab.

Conclusions: Only a minority (three of eight) of patients in our series of adult patients with FSGS showed a positive influence of rituximab. More studies are necessary to characterize further the optimal dosages and the mechanisms of action of rituximab in FSGS.

Citing Articles

Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome.

Feder O, Amsterdam D, Ershed M, Grupper A, Schwartz D, Kliuk-Ben Bassat O BMC Nephrol. 2025; 26(1):126.

PMID: 40050772 PMC: 11887153. DOI: 10.1186/s12882-025-04035-0.

Rituximab in Steroid-Dependent Podocytopathies.

Costa C, Antunes A, Oliveira J, Pereira M, Godinho I, Fernandes P Glomerular Dis. 2024; 4(1):129-136.

PMID: 39144474 PMC: 11324230. DOI: 10.1159/000539922.

Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy.

Zhang Y, Yang J, Li J, Sun J, Zhou L, Xu D BMC Nephrol. 2024; 25(1):86.

PMID: 38448810 PMC: 10918849. DOI: 10.1186/s12882-024-03521-1.

Review of the Role of Rituximab in the Management of Adult Minimal Change Disease and Immune-Mediated Focal and Segmental Glomerulosclerosis.

Aslam A, Koirala A Glomerular Dis. 2023; 3(1):211-219.

PMID: 37901702 PMC: 10601923. DOI: 10.1159/000533695.

A randomized controlled trial of preemptive rituximab to prevent recurrent focal segmental glomerulosclerosis post-kidney transplant (PRI-VENT FSGS): protocol and study design.

Rheault M, Amaral S, Bock M, Chambers E, Chavers B, Ters M Front Nephrol. 2023; 3:1181076.

PMID: 37675355 PMC: 10479749. DOI: 10.3389/fneph.2023.1181076.

References

Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-LE Camus C, Afanetti M . Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008; 23(8):1269-79. DOI: 10.1007/s00467-008-0814-1. View

Kamar N, Faguer S, Esposito L, Guitard J, Nogier M, Durand D . Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol. 2007; 67(4):250-4. DOI: 10.5414/cnp67250. View

Suri M, Tran K, Sharma A, Filler G, Grimmer J . Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int Urol Nephrol. 2008; 40(3):807-10. DOI: 10.1007/s11255-008-9393-0. View

Vincenti F, Ghiggeri G . New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005; 5(6):1179-85. DOI: 10.1111/j.1600-6143.2005.00968.x. View

Maloney D, Grillo-Lopez A, White C, Bodkin D, Schilder R, Neidhart J . IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90(6):2188-95. View

Fervenza F, Cosio F, Erickson S, Specks U, Herzenberg A, Dillon J . Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2007; 73(1):117-25. DOI: 10.1038/sj.ki.5002628. View

Gilbert R, Hulse E, Rigden S . Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006; 21(11):1698-700. DOI: 10.1007/s00467-006-0228-x. View

Gossmann J, Scheuermann E, Porubsky S, Kachel H, Geiger H, Hauser I . Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int. 2007; 20(6):558-62. DOI: 10.1111/j.1432-2277.2007.00477.x. View

Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C . Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003; 14(7):1851-7. DOI: 10.1097/01.asn.0000071511.35221.b3. View

10.

Cattran D, Appel G, Hebert L, Hunsicker L, Pohl M, Hoy W . A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999; 56(6):2220-6. DOI: 10.1046/j.1523-1755.1999.00778.x. View

11.

Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M . Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005; 20(11):1660-3. DOI: 10.1007/s00467-005-2013-7. View

12.

Grimbert P, Valanciute A, Audard V, Pawlak A, Le gouvelo S, Lang P . Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization. J Exp Med. 2003; 198(5):797-807. PMC: 1865475. DOI: 10.1084/jem.20030566. View

13.

Yang T, Nast C, Vo A, Jordan S . Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant. 2007; 23(1):377-80. DOI: 10.1093/ndt/gfm592. View

14.

Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M . A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991; 40(3):453-60. DOI: 10.1038/ki.1991.232. View

15.

Benz K, Dotsch J, Rascher W, Stachel D . Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004; 19(7):794-7. DOI: 10.1007/s00467-004-1434-z. View

16.

Yabu J, Ho B, Scandling J, Vincenti F . Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 2007; 8(1):222-7. DOI: 10.1111/j.1600-6143.2007.02021.x. View

17.

Savin V, Sharma R, Sharma M, McCarthy E, Swan S, Ellis E . Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996; 334(14):878-83. DOI: 10.1056/NEJM199604043341402. View

18.

Marks S, McGraw M . Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation?. Pediatr Nephrol. 2006; 22(1):158-60. DOI: 10.1007/s00467-006-0260-x. View

19.

Hristea D, Hadaya K, Marangon N, Buhler L, Villard J, Morel P . Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int. 2006; 20(1):102-5. DOI: 10.1111/j.1432-2277.2006.00395.x. View

20.

Mathieson P . Proteinuria and immunity--an overstated relationship?. N Engl J Med. 2008; 359(23):2492-4. DOI: 10.1056/NEJMcibr0806881. View